PTPA and B-cell chronic lymphocytic leukemia: These results highlight the relevance of PP2A-reactivating strategies in CLL by identifying in DT-061 a new drug with preclinical activity in CLL, that may have important implications, especially in those cases where kinase-targeted therapies fail to function.